Key result
Olmesartan treatment improved fractional shortening and attenuated oxidative stress, endoplasmic reticulum stress, and inflammatory cytokines in rats with experimental autoimmune myocarditis.
Why the study?
Does olmesartan improve myocardial function and reduce inflammatory and stress markers in rats with experimental autoimmune myocarditis?
Does olmesartan improve myocardial function and reduce inflammatory and stress markers in rats with experimental autoimmune myocarditis?
Olmesartan attenuates oxidative stress, ER stress, and inflammation, improving cardiac function in a rat model of autoimmune myocarditis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ARB therapy in inflammatory myocarditis; human trials required before any clinical consideration.
Studies have demonstrated that angiotensin II has been involved in immune and inflammatory responses which might contribute to the pathogenesis of immune-mediated diseases. Recent evidence suggests that oxidative stress may play a role in myocarditis. Here, we investigated whether olmesartan, an AT(1)R antagonist protects against experimental autoimmune myocarditis (EAM) by suppression of oxidative stress, endoplasmic reticulum (ER) stress and inflammatory cytokines. EAM was induced in Lewis rats by immunization with porcine cardiac myosin, were divided into two groups and treated with either olmesartan (10 mg/kg/day) or vehicle for a period of 21 days. Myocardial functional parameters measured by hemodynamic and echocardiographic analyses were significantly improved by the treatment with olmesartan compared with those of vehicle-treated rats. Treatment with olmesartan attenuated the myocardial mRNA expressions of proinflammatory cytokines, [Interleukin (IL)-1β, monocyte chemoattractant protein-1, tumor necrosis factor-α and interferon-γ)] and the protein expression of tumor necrosis factor-α compared with that of vehicle-treated rats. Myocardial protein expressions of AT(1)R, NADPH oxidase subunits (p47phox, p67phox, gp91phox) and the expression of markers of oxidative stress (3-nitrotyrosine and 4-hydroxy-2-nonenal), and the cardiac apoptosis were also significantly decreased by the treatment with olmesartan compared with those of vehicle-treated rats. Furthermore, olmesartan treatment down-regulated the myocardial expressions of glucose regulated protein-78, growth arrest and DNA damage-inducible gene, caspase-12, phospho-p38 mitogen-activated protein kinase (MAPK) and phospho-JNK. These findings suggest that olmesartan protects against EAM in rats, at least in part via suppression of oxidative stress, ER stress and inflammatory cytokines.
No takes yet. Share an insight, caveat, or question.
Sukumaran et al. (2011) studied Experimental Autoimmune Myocarditis (EAM) (n=22). Olmesartan vs. Vehicle was evaluated on Fractional shortening (FS) (p=<0.01). Olmesartan treatment improved fractional shortening and attenuated oxidative stress, endoplasmic reticulum stress, and inflammatory cytokines in rats with experimental autoimmune myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: